Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease
Cited 7 times inCited 9 times in
- Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease
- Do, Yoonkyung; Rafi-Janajreh, AQ; Mckallip, RJ; Nagarkatti, PS; Nagarkatti, M
- Activation-induced cell death; Apoptosis; Autoantibody; Double-negative T cells; Lupus
- Issue Date
- OXFORD UNIV PRESS
- INTERNATIONAL IMMUNOLOGY, v.15, no.11, pp.1327 - 1340
- Patients with mutations in Fas develop autoimmune lymphoproliferative disease (ALPS), While their family members with similar mutations are often normal, thereby suggesting that additional factors may play a role in the development of ALPS. In the current study, we tested the role of CD44 in the development of lymphoproliferative disease by generating CD44 -/-/Fas -/-mice, which failed to express CD44 and Fas, and compared them to CD44 +/+/Fas -/- mice that expressed CD44, but not Fas. The results showed that CD44 -/-/Fas -/- mice developed a more severe lymphoproliferative and autoimmune disease when compared to CD44 +/+/Fas -/- mice. This was indicated by increased numbers of cells in their lymph nodes, and a greater proportion of B220 +CD4 -CD8 - (double-negative) T cells as well as antibodies against single-stranded DNA and chromatin. The heightened severity of lymphoproliferative disease seen in CD44 -/-/Fas -/- mice correlated with increased resistance of T cells, but not B cells, to undergo activation-induced cell death (AICD). The current study suggests that deficiency in CD44 in combination with a defect in one of the molecules involved in the death receptor family such as Fas can further down-regulate AICD, and exacerbate the lymphoproliferative and autoimmune disease.
- ; Go to Link
- Appears in Collections:
- BME_Journal Papers
- Files in This Item:
can give you direct access to the published full text of this article. (UNISTARs only)
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.